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The binding subunit of pertussis toxin (PTX-B) has been shown recently to inhibit the entry and postentry events in HIV-1
replication in primary T lymphocytes and monocyte-derived macrophages. While the effect of PTX-B on HIV-1 entry was
shown to involve CCR5 desensitization, the mechanism of postentry inhibition remained unclear. In T lymphocytes, PTX-B
affected transcription or stability of Tat-stimulated HIV-1 mRNAs. In this study, we sought to identify the mechanism of
postentry inhibition of HIV-1 replication by PTX-B in U-937 promonocytic cells. We demonstrate that in these cells PTX-B
inhibits expression of luciferase reporter gene controlled by the HIV-1 LTR promoter. This effect is Tat-independent and is
not restricted to the HIV-1 LTR promoter. Instead, PTX-B activity is mediated through suppression of the cellular transcription
factor, NF-B. PTX-B inhibits phosphorylation and nuclear translocation of the p65 subunit of NF-B. This effect is
independent of the cytoplasmic NF-B inhibitor, IB, as PTX-B stimulates phosphorylation and subsequent degradation of
this protein. The suppressive activity of PTX-B on NF-B p65 phosphorylation and nuclear translocation is delayed,
suggesting that PTX-B signaling might initiate synthesis and cytoplasmic accumulation of a p65 phosphorylation inhibitor.INTRODUCTION
Pertussis toxin, the major virulence factor of Bordetella
pertussis, is a 105-kDa noncovalently linked heterohex-
americ protein composed of the A (active)-promoter and
the B (binding)-oligomer. The A-promoter is an enzymat-
ically active subunit exhibiting ADP ribosyltransferase
activity responsible for ribosylation and inactivation of
Gi-like proteins (Katada et al., 1983). The pentameric
B-oligomer is composed of S2-S4 and S3-S4 dimers held
together by the S5 subunit (Latif et al., 2001; Wang and
Oppenheim, 1999). The main function of the PTX-B is
binding of pertussis toxin to target cells (Wong and
Rosoff, 1996). However, PTX-B activity is not limited to the
binding function; it also initiates signaling events in tar-
get cells (Alfano et al., 1999; Li and Wong, 2001; Rosoff et
al., 1987; Stewart et al., 1989; Thom and Casnellie, 1989).
This signaling activity is mediated by an as yet uniden-
tified receptor. Possible candidates include a 43-kDa
protein in T lymphocytes (Rogers et al., 1990), the CD11b-
CD18 integrin (Wong et al., 1996; Wong and Luk, 1997),
and the CD14 molecule in myelomonocytic cells (Li and
1 To whom correspondence and reprint requests should be addressed
at The George Washington University Medical Center, Department of195Wong, 2000, 2001). PTX-B signaling activity produces
multiple effects, including chemotaxis and cell prolifera-
tion (Alfano et al., 1999; Gray et al., 1989; Kolb et al.,
1990). Recently, it was shown that a highly purified S3-S4
dimer induces proliferation of T cells and probably ac-
counts for the mitogenic activity of the B-oligomer (Latif
et al., 2001). PTX-B signaling also intensifies Th1-depen-
dent immune response through up-regulation of IFN-
and IL-2 (Ryan et al., 1997; Stewart et al., 1989) and
inhibition of prostaglandin production (O’Neill et al.,
1992).
Recently, we demonstrated that PTX-B, through its
signaling activity, induces selective heterologous desen-
sitization of the major HIV-1 chemokine coreceptor,
CCR5, in activated primary CD4 T lymphocytes (Alfano
et al., 1999). CCR5 desensitization correlated with sup-
pression of entry of the CCR5-dependent HIV-1 strains
(Alfano et al., 1999). However, PTX-B also inhibited rep-
lication of the X4 HIV-1 strains in peripheral blood mono-
nuclear cells (PBMC) (Alfano et al., 1999, 2000). This
activity was independent of the PTX-B effect on HIV-1
coreceptors and suggested additional, postentry mech-
anisms of suppression (Alfano et al., 2000). Indeed, anal-
ysis of HIV-1 RNA production demonstrated that PTX-B
suppressed HIV-1 RNA synthesis in cultures of X4 HIV-
1-infected PBMC and reduced Tat-dependent expression© 2002 Elsevier Science (USA)
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long terminal repeat (LTR) (Alfano et al., 2000). Therefore,
in T cells PTX-B inhibits entry of R5 HIV-1 strains and
postentry events for both R5 and X4 viruses. Analysis of
PTX-B anti-HIV activity was recently extended to mono-
cytes/macrophages (Alfano et al., 2001). This study dem-
onstrated that, similar to T lymphocytes, PTX-B inhibits
both entry and postentry steps of R5 HIV-1 infection.
PTX-B also strongly inhibited virus expression in TNF--
and IL-6-stimulated promonocytic cells chronically in-
fected with HIV-1. These results suggest that the mech-
anisms of HIV-1 inhibition by PTX-B might be similar in
both T cells and macrophages. While mechanisms of
entry inhibition have been analyzed in detail (Alfano et
al., 1999, 2000), little is known about PTX-B effects on the
postentry step of HIV-1 replication. This postentry activity
most likely involves inhibition of transcription or desta-
bilization of Tat-dependent HIV-1 RNAs (Alfano et al.,
2000).
The above-referenced study (Alfano et al., 2001)
showed that PTX-B suppressed TNF--stimulated HIV-1
replication in promonocytic cells. Since TNF- is a clas-
sical transcriptional stimulator of viral expression, mainly
operating via activation of the cellular transcription factor
NF-B (Antoni et al., 1994; Griffin et al., 1989; Osborn et
al., 1989; Vicenzi et al., 1997), it appears likely that NF-B
is involved in the mechanism of suppression of HIV-1
LTR-driven transcription by PTX-B. NF-B is the main
cellular transcription factor regulating HIV-1 expression
(Nabel and Baltimore, 1987). The HIV-1 LTR contains two
binding sites for cellular proteins belonging to the NF-
B/Rel family (Fig. 1A). This protein family includes p65
(RelA), p50, p52, RelB, and c-Rel polypeptides, which
form homo- and heterodimers (Baeuerle and Baltimore,
1996). The most abundant of these dimers is the NF-B
p65/p50 heterodimer, although the homodimers of p65
and p50 are also found in different cell types (Haskill et
al., 1991; Siebenlist et al., 1994; Simeonidis et al., 1997;
Thompson et al., 1995). In the cytoplasm, NF-B p65/p50
heterodimers exist as a complex with the inhibitor pro-
tein IB, which inactivates the NF-B heterodimers by
masking their nuclear localization sequences (Ganchi et
al., 1992; Henkel et al., 1992; Phelps et al., 2000a). Acti-
vation of signaling pathways by such extracellular sig-
nals as TNF-, IL-1, phorbol esters, or lipopolysaccharide
leads to phosphorylation of IB at two amino-terminal
serine residues (S32, S36) (reviewed in Ghosh et al.,
1998; Karin and Ben Neriah, 2000). Phosphorylation of
these targets stimulates rapid proteolytic degradation of
IB via the 26 S proteasome (Baeuerle and Baltimore,
1996), allowing active NF-B to translocate into the nu-
cleus (Mercurio et al., 1997; Roff et al., 1996; Scherer et
al., 1995; Yaron et al., 1997) and to activate transcription
from a wide variety of promoters, including the HIV-1 LTR
(Griffin et al., 1989; Moses et al., 1994). Another mecha-
nism regulating the transcriptional activity of NF-B is
through phosphorylation of the p65 subunit (Mercurio et
al., 1999; Wang and Baldwin, 1998; Zhong et al., 1997).
Extracellular stimuli, such as TNF-, are believed to
induce p65 phosphorylation (Mercurio et al., 1997, 1999;
Schwabe et al., 2001; Wang and Baldwin, 1998), which
occurs in the cytoplasm prior to p65 nuclear transloca-
tion (Sakurai et al., 1999). Phosphorylation of p65 is
considered to be an important step in the up-regulation
of the transcriptional activity of NF-B, independent of its
DNA-binding activity (Schwabe et al., 2001).
In this study, we investigated possible mechanisms of
PTX-B inhibitory effect on HIV-1 transcription in promono-
cytic cells U-937. Our results suggest that PTX-B targets
the p65 subunit of the NF-B transcription factor.
RESULTS
PTX-B inhibits luciferase reporter gene expression
through suppression of NF-B activity
Recently, it was demonstrated that PTX-B effectively
inhibits HIV-1 replication in U-937 cells at a postentry
level of infection, as well as virus expression in chroni-
cally infected U1 cells stimulated with proinflammatory
cytokines (TNF-, IL-6) (Alfano et al., 2001). This inhibi-
tory activity of PTX-B was hypothesized to target either
transcription, or splicing, or stability of viral mRNAs.
To analyze the mechanisms of PTX-B suppressing
activity, we generated a series of pLTR–luciferase con-
structs containing the luciferase reporter gene controlled
by the complete 5 LTRLAI plus the leader region up to the
beginning of the GAG open reading frame (nt 1–789,
where nt  1 is the start of the U3 region in the 5 LTR)
and carrying mutations in the TAR region and in different
transcription factor binding sites of the 5 LTR (Fig. 1A).
The five resulting plasmids were designated pLTRluc-wt,
pLTRluc-TAR, pLTRluc-mut-Sp1(I,II,III), pLTRluc-mut-AP-
1(I,II,III)/NF-AT, and pLTRluc-mut-B (Fig. 1A). These
plasmids were transiently transfected into U-937 cells.
Incubation of transfected cells with 2.5 nM PTX-B for 48 h
resulted in approximately 60% suppression of luciferase
activity in cell lysates with the pLTRluc-wt construct (Fig.
1B). Unlike Jurkat cells (a T-cell line), where PTX-B inhib-
itory effect was specific only for Tat-dependent transcrip-
tion (Alfano et al., 2000), the effect in U-937 promonocytic
cell line was Tat-independent. Indeed, the inhibitory ef-
fect of PTX-B on luciferase expression from HIV-1 LTR
was similar in the presence or absence of Tat (coex-
pressed from pcDNA1/Tat plasmid) (Fig. 1B). Further-
more, Renilla luciferase expression from the CMV pro-
moter was also suppressed (Fig. 1B, pRL-CMV).
In order to check whether the inhibitory activity of
PTX-B was transcription-associated and to identify the
transcription factor(s) involved, we used recombinant
plasmids encoding the luciferase gene controlled by
HIV-1 LTR promoter with point mutations in several cel-
lular transcription factor binding sites and in the TAR
region (Fig. 1A). These experiments demonstrated that
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the PTX-B inhibitory effect on luciferase gene expression
was not reduced by inactivating mutations in the TAR
region, in the three Sp1 sites (I, II, III), in the three AP-1
sites (I, II, III), or NF-AT binding sites of the HIV-1 LTR
region (Fig. 1C). In contrast, mutation in the two B sites
of the HIV-1 enhancer (pLTRluc-mut-B) resulted in a
complete loss of sensitivity of luciferase expression to
PTX-B inhibitory activity (Fig. 1C). These results suggest
that the suppressing effect of PTX-B on luciferase gene
expression is transcription-associated and is mediated
by inhibition of NF-B activity. Binding sites for this uni-
versal transcription activator can be found in both the
HIV-1 LTR and the CMV early enhancer/promoter se-
quences.
PTX-B reduces the level of nuclear NF-B p65 subunit
To investigate the link between the PTX-B effect and
NF-B, we cotransfected U-937 cells with pLTRluc-wt
and with expression vectors for the NF-B subunit p65 or
p50 (pRSV-p65 or/and pRSV-p50) and treated them with
PTX-B (Fig. 2A). The transfection approach provides an
FIG. 1. PTX-B inhibits NF-B-mediated luciferase reporter gene expression. (A) Schematic representation of the LTR promoter region in the
constructs used for this study. The LTR is derived from the HIV-1 LAI strain and was cloned upstream of the firefly luciferase reporter gene in the
pGL2-Basic vector. Point mutations were introduced into indicated transcription factor binding sites and in the TAR sequence. Mutated sites are
marked with asterisks. (B) PTX-B activity is not HIV-1 LTR-specific. Triplicate cultures of U-937 cells were transfected with pLTRluc-wt, pRL-CMV
(encoding Renilla luciferase under control of the CMV promoter), or cotransfected with pLTRluc-wt and the HIV-1 Tat expression vector pcDNA1/Tat.
Three hours posttransfection, cells were treated or not for 48 h with PTX-B and lysed for luciferase activity analysis. Luciferase activity is presented
as percentage of activity in PTX-B-untreated cells. Results are shown for one representative experiment of three total and are presented as mean 
SD. (C) PTX-B activity is NF-B-dependent. U-937 cells were cotransfected with the various constructs shown in (A) with or without pcDNA1/Tat. PTX-B
treatment and luciferase activity measurement was performed as described in (B). Results are mean  SD of three replicates, except cotransfections
of pcDNA1/Tat with pLTRluc-mut-Sp1 and pLTRluc-mut-AP-1/NF-AT that were performed one time.
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opportunity to investigate the effect of PTX-B on individ-
ual subunits of NF-B. Expression of the recombinant
p65 subunit resulted in a fivefold increase of HIV-1 LTR-
driven luciferase transcription, whereas p50 subunit ini-
tiated only a twofold stimulation (Fig. 2A). Coexpression
of p50 and p65 subunits led to a fourfold increase in
luciferase expression (Fig. 2A). It should be noted that
the amount of pRSV-p65 and pRSV-p50 used in the co-
transfection experiment was only half of the amount
used for individual expression of these factors, thus
explaining the lower activation effect of the p65/p50
combination compared to p65 alone. These data are
consistent with a generally accepted view that p65 is a
transcriptionally active member of the NF-B family,
whereas p50 primarily serves as a DNA-binding subunit
(reviewed in Karin and Ben Neriah, 2000; Liou and Bal-
timore, 1993). Incubation of transfected cells with PTX-B
for 48 h resulted in suppression of luciferase activity;
however, the rate of suppression varied. Maximal sup-
pression was observed with pRSV-p65 (more than three-
fold inhibition, Fig. 2A). Less than a twofold inhibition
was detected with pRSV-p50 (Fig. 2A). The inhibitory
effect in cells cotransfected with p65 and p50 subunits
was slightly lower than in p65-transfected cells.
NF-B is maintained in a complex with IB in the
cytoplasm of resting cells and enters the nucleus to bind
specific DNA sites in response to various stimuli, includ-
ing viral proteins, ultraviolet irradiation, and proinflam-
FIG. 2. PTX-B inhibits nuclear accumulation and activity of NF-B. (A) Analysis of PTX-B effect on transcriptional activity of NF-B p65 and p50
subunits. U-937 cells were either transfected with pLTRluc-wt (1 g) or cotransfected with pLTRluc-wt (1 g) and pRSV-p65 (0.01 g), pLTRluc-wt (1
g) and pRSV-p50 (0.01 g), or pLTRluc-wt (1 g), pRSV-p65 (0.005 g), and pRSV-p50 (0.005 g). Three hours posttransfection, cells were treated
or not for 48 h with PTX-B and lysed for luciferase activity analysis. Luciferase activity is shown as percentage of activity in PTX-B-untreated cells
transfected with pLTRluc-wt (control). Results are mean SD of three replicates. One representative experiment of two performed is shown. (B) PTX-B
inhibits nuclear accumulation of NF-B p65 subunit. U-937 cells were treated or not with 2.5 nM PTX-B and incubated for 48 h. Thirty minutes prior
to harvesting, cells were stimulated or not with TNF- (0.1 ng/ml). Cytoplasmic lysates and nuclear extracts were analyzed by Western blotting using
rabbit anti-p65 (C-20) or anti-p50 (H-119) polyclonal antibodies. Mouse anti-actin (AC-40) and anti-histone H1 (AE-4) monoclonal antibodies were used
to normalize protein concentration in the preparations. (C) Quantification of Western blotting results. Western blotting data from three independent
experiments examining nuclear p65 and p50 (representative experiment is shown in (B)) were analyzed using UTHSCSA Image Tool Version 3.0
program. Results show mean gray values of the bands  SE and are presented as percentage of the background. (D) Analysis of PTX-B effects on
TNF--induced activation of NF-B subunits. U-937 cells were incubated or not with 2.5 nM PTX-B for 48 h and then stimulated with TNF- (0.1 ng/ml)
for 30 min. Nuclear extracts were prepared and tested for NF-B subunit activity by EMSA (lanes 1, 2) and supershift (lanes 3–6) assays, as described
under Materials and Methods. Bands corresponding to supershifted NF-B complexes are marked by asterisks.
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matory cytokines such as TNF- and IL-1 (Mercurio et
al., 1997; Phelps et al., 2000a,b). In order to evaluate
possible effects of PTX-B on nuclear localization and
DNA-binding activity of NF-B, we analyzed p65 and p50
NF-B subunits in the nuclear and cytoplasmic fractions
of U-937 cells preincubated with PTX-B and activated or
not with TNF-. In our previous study (Alfano et al., 2001),
we determined that optimal stimulation time to detect
TNF--induced NF-B in U1 cells (derivatives of U-937)
was 30 min. Western blotting analysis of U-937 cells
using anti-p65 and anti-p50 antibodies demonstrated
that PTX-B slightly (approximately 1.6-fold, Fig. 2B and
2C) reduced the nuclear, but not the cytoplasmic, NF-B
p65 subunit in nonactivated cells, and substantially (7.5-
fold) diminished the nuclear p65 level in TNF--stimu-
lated cells. In contrast, the amount of p50 subunit in both
cytoplasmic and nuclear compartments did not change
after PTX-B treatment (Figs. 2B and 2C). PTX-B-induced
reduction of nuclear p65 in TNF--treated cells was also
demonstrated by the supershift assay (Fig. 2D, lanes 3
and 4). Consistent with the results presented in Figs.
2A–2C, this assay did not detect reduction of nuclear p50
in PTX-treated cells (Fig. 2D, lanes 5 and 6). The p50
subunit likely accounts for the binding activity observed
in PTX-B-treated cells by EMSA (Fig. 2D, lanes 1 and 2).
Taken together, our results suggest that the p65 sub-
unit of NF-B provides stronger activation of HIV-1 LTR-
driven transcription than p50 in U-937 promonocytic
cells. The inhibitory effect of PTX-B appears to be
achieved by reduction of the steady-state nuclear levels
of the p65, but not the p50, subunit. PTX-B-induced re-
duction of luciferase activity in pRSV-p50-transfected
cells (Fig. 2A) can be explained by the effect of PTX-B on
the basic activity level of the endogenous p65 subunit.
Effect of PTX-B on nuclear p65 is IB-independent
One possible mechanism for the observed inhibitory
effect of PTX-B on NF-B p65 nuclear import is through
suppression of IB phosphorylation and degradation.
We therefore analyzed IB phosphorylation and degra-
dation in the cytoplasmic fraction of PTX-B-treated and
untreated U-937 cells activated or not with TNF- (Fig. 3).
We chose a 7-min stimulation time with TNF- because
previous study (Manna et al., 2000) demonstrated that
maximal effect on IB phosphorylation and degradation
occurred between 7 and 15 min of TNF- stimulation.
Surprisingly, PTX-B-pretreated cells demonstrated more
IB degradation than PTX-B-untreated cells (Fig. 3, up-
per panel). Despite low levels of total IB, antibody to
phosphorylated IB detected amounts of this protein
that were substantially higher than in untreated cells
(bottom panel). Interestingly, there was considerably
more phosphorylated IB in TNF--stimulated PTX-B-
treated cells than in untreated cells, suggesting that
PTX-B-induced phosphorylation of IB is very brisk.
These results suggest that PTX-B contributes to phos-
phorylation and subsequent degradation of IB and
therefore is expected to stimulate nuclear accumulation
of NF-B. Since we observed not an increase but a
decrease in the steady-state level of p65, we conclude
that the inhibitory effect of PTX-B is independent of IB.
PTX-B effect on NF-B p65 is delayed
Results presented above illustrate the analysis of
U-937 cells incubated with PTX-B for 48 h. Previous study
using EMSA and supershift assays of U1 cells pretreated
with PTX-B for 20 min and 4 h did not reveal any PTX-B
effects on NF-B activity (Alfano et al., 2001). However, a
20-min incubation of these cells with PTX-B followed by
activation with TNF- inhibited HIV-1 expression mea-
sured 72 h after stimulation, as well as HIV-1 RNA accu-
mulation measured at 16 h. Taken together with our
results, these data suggest that the effect of PTX-B is
delayed.
To analyze the time course of PTX-B effect on LTR-
driven transcription, we incubated pLTRluc-wt-trans-
fected U-937 cells with PTX-B for 24, 48, and 72 h (Fig.
4A). Measurement of luciferase activity displayed maxi-
mal inhibitory effect at the 48-h time point (60% suppres-
sion). No suppression was observed with shorter incu-
bation time (24 h). Longer incubation time (72 h) de-
creased the inhibitory effect to 30%, probably as a
result of culture media depletion. Consistent with previ-
ous results, no PTX-B inhibitory activity was observed
with the pLTRluc-mut-B plasmid (Fig. 4A).
To further explore the delayed effect of PTX-B, we
incubated pLTRluc-wt-transfected U-937 cells with PTX-B
for 2 and 24 h and then postincubated in culture media
without the B-oligomer for 46 and 24 h, respectively. A
time-dependent increase in PTX-B inhibitory activity was
observed (Fig. 4B). This inhibitory effect partially corre-
FIG. 3. PTX-B stimulates IB phosphorylation and degradation.
U-937 cells were incubated or not with 2.5 nM PTX-B for 48 h and then
were either stimulated with TNF (0.1 ng/ml) for 7 min or left unstimu-
lated. Cytoplasmic lysates were analyzed by Western blotting using
rabbit anti-IB or anti-phospho-IB (P-IB) polyclonal antibodies.
Mouse anti-actin (AC-40) monoclonal antibody was used to normalize
protein concentration in the cytoplasmic preparations.
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lated with the dynamics of nuclear accumulation of
NF-B p65 subunit in the treated cells (Figs. 4C and 4D).
The maximal level of inhibition (approximately fivefold)
was reached after 24 h incubation with the B-oligomer
(Figs. 4C and 4D). Consistent with the report by Alfano et
al. (2001), Western blot analysis of the nuclear fraction of
U-937 cells incubated with PTX-B for 2 h, performed just
after incubation (without long-time postincubation peri-
od), did not show any inhibition of the NF-B p65 nuclear
accumulation (data not shown). This delayed effect of
PTX-B suggests involvement of an intracellular synthetic
pathway initiated by PTX-B signaling that leads to IB-
independent suppression of p65 nuclear accumulation
and LTR-driven transcription. Although we cannot for-
mally exclude the possibility that the observed delay in
PTX-B activity reflects its intracellular accumulation, it
appears unlikely, as there is no published evidence for
direct interaction between PTX-B and cellular signaling
proteins.
PTX-B inhibits phosphorylation of NF-B p65 subunit
PTX-B treatment of U-937 cells stimulates IB phos-
phorylation and degradation in response to TNF- acti-
vation, but inhibits NF-B p65 nuclear accumulation. Be-
cause p65 is also phosphorylated in response to TNF-
signaling and because this mechanism is believed to
contribute to up-regulation of the transcriptional activity
of NF-B (Mercurio et al., 1997, 1999; Sizemore et al.,
1999, 2002; Schwabe et al., 2001; Wang and Baldwin,
1998), we analyzed a possible effect of PTX-B on phos-
phorylation of NF-B p65. For this analysis, we per-
formed metabolic labeling of U-937 cells incubated or not
with PTX-B (for 24 h) and TNF- (for 7–40 min), and
immunoprecipitated p65, p50, and their precursor, p105,
FIG. 4. Time course analysis of PTX-B effects on luciferase reporter gene expression and nuclear accumulation of NF-B. (A) Triplicate cultures
of U-937 cells were transfected with pLTRluc-wt or with pLTRluc-mut-B. Cells were treated or not with PTX-B at 3 h posttransfection, incubated with
PTX-B for 24, 48, or 72 h, and harvested. Luciferase activity was measured in total cell lysates and is presented as percentage of activity in
PTX-B-untreated cells for each time point. Results are presented as mean  SD. (B) Triplicate cultures of U-937 cells were transfected with
pLTRluc-wt. Cells were treated or not with 2.5 nM PTX-B at 3 h posttransfection, incubated with PTX-B for 2, 24, or 48 h, washed, and cultured without
PTX-B for 46, 24, or 0 h, respectively. Luciferase activity was measured as in (A). (C) The effect of PTX-B on nuclear translocation of NF-B p65 subunit
is delayed. Cells were treated or not with 2.5 nM PTX-B, incubated with PTX-B for 2, 24, or 48 h, washed, and cultured without PTX-B for 46, 24, or
0 h, respectively. At the 48-h time point, cells were stimulated with TNF- (0.1 ng/ml) for 30 min. Nuclear extracts were analyzed by Western blotting
as described in the legend to Fig. 2B. (D) Quantification of Western blotting results. Western blotting data from two independent experiments
examining nuclear p65 (representative experiment is shown in (C)) were analyzed using UTHSCSA Image Tool Version 3.0 program. Results show
mean gray values of the bands  SE and are presented as percent of the background.
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from the total cell lysates. It should be noted here that
due to excess of cytoplasmic over nuclear NF-B, this
analysis mostly addresses cytoplasmic NF-B phosphor-
ylation. As shown in Fig. 5A, TNF--stimulated phosphor-
ylation of p65 was suppressed in PTX-B-treated cells.
The rate of phosphorylation of p65 molecules was grad-
ually increasing during the time of TNF- stimulation in
PTX-B-untreated cells (Fig. 5A). In contrast, no increase
was observed in PTX-B-treated U-937 cells (Fig. 5A).
Interestingly, immunoprecipitation of the cell lysates with
anti-p50 antibodies revealed significant levels of phos-
phorylation of the p50 protein and p105 precursor, the
amino-terminal part of which forms the p50 subunit (Fig.
5B). Recent publications (Cohen et al., 2001; Heissmeyer
et al., 1999; Orian et al., 2000) reported that chemokine-
induced, IB kinase-mediated phosphorylation of the
p105 C-terminal domain leads to processing of the pre-
cursor, whereas phosphorylation of the p50 subunit con-
tributes to the DNA-binding activity of NF-B (Koul et al.,
2001). Although we observed inhibition of p105 phos-
phorylation by PTX-B, we did not see PTX-B-initiated
suppression of p50 phosphorylation and nuclear accu-
mulation (Figs. 2B and 2C; Fig. 5B).
Taken together, these results indicate that PTX-B in-
hibits phosphorylation of the NF-B p65 subunit. We
suggest that this effect mediates the decrease of p65
steady-state levels and suppression of HIV-1 LTR-driven
transcription inhibitory activity by PTX-B.
DISCUSSION
Mononuclear phagocytes are one of two major cell
types infected during a natural course of HIV disease.
They are known to play an important role both as viral
reservoirs and as a source of replicating HIV during all
stages of disease (Igarashi et al., 2001; Orenstein et al.,
1997). Therefore, it is of paramount importance to identify
mechanisms of HIV replication in these cells and agents
that would inhibit infection of macrophages. Recently, it
was demonstrated that the B-oligomer of PTX-B inhibits
HIV-1 replication in monocyte-derived macrophages at
both entry and postentry steps (Alfano et al., 2001). While
inhibition of HIV-1 entry by PTX-B was shown to be
mediated through CCR5 (Alfano et al., 1999), the mech-
anism of postentry effect was not identified. In the
present study, we demonstrate that the PTX-B inhibits
HIV-1 LTR-controlled transcription in U-937 promonocytic
cells. This inhibitory activity is not limited to Tat-depen-
dent transcripts, because PTX-B also suppressed tran-
scription from the CMV promoter, as well as from the LTR
promoter with mutated TAR or in the absence of the
Tat-expressing vector. This effect is delayed and is me-
diated by inhibition of the nuclear accumulation of the
NF-B p65 subunit. The inhibitory effect of PTX-B on the
NF-B p65 subunit is IB-independent, because PTX-B
activates phosphorylation and degradation of IB.
Our study confirms conclusions reached in our previ-
ous work (Alfano et al., 2001) that described the PTX-B
effects on HIV-1 expression in a TNF-- and IL-6-acti-
vated U1 cell line, which is an HIV-1 chronically infected
U-937-derived line (Folks et al., 1987). Similar to results of
this report, PTX-B activity in U1 cells was shown to be
transcription-mediated. However, in the previous study
we did not find any effect of PTX-B on NF-B. This
inconsistency with the results presented here is likely
due to differences in the time of analysis. EMSA and
supershift analyses in our previous study were per-
formed shortly after PTX-B treatment (20 min and 4 h),
while here we demonstrate that PTX-B stimulates a de-
layed response in U-937 cells, which is observed only
after a prolonged (24–48 h) postincubation period. This
delayed response suggests that the effect of PTX-B on
NF-B is indirect and might be mediated by induction of
a synthetic pathway of a factor that inhibits p65 nuclear
accumulation.
Our results indicate that PTX-B induces phosphoryla-
tion and subsequent degradation of IB in U-937 cells.
Phosphorylation of IB family members, when initiated
by extracellular stimuli, is carried out by two related IB
kinases, IKK and IKK. These kinases are found as
homo- or heterodimeric IKK complexes that directly
phosphorylate two N-terminal serine residues in IBs
(DiDonato et al., 1997; Mercurio et al., 1997; Zandi et al.,
1997). Recently, it was shown that the IKK is mainly
responsible for cytokine-induced IB degradation (Hu et
al., 1999; Takeda et al., 1999). PTX-B, through its signaling
activity, might feed into this pathway and activate the
components of the IKK complex, leading to phosphory-
lation and degradation of IB.
Recent publications elucidated the mechanism of
FIG. 5. Analysis of PTX-B effects on NF-B phosphorylation. (A)
PTX-B inhibits TNF--induced phosphorylation of NF-B p65 subunit.
U-937 cells were treated or not with PTX-B for 24 h followed by
incubation in a phosphate-free medium without PTX-B for additional
24 h. Cells were then incubated with [32P]orthophosphate for 2 h and
then stimulated with TNF- (0.1 ng/ml) for indicated time intervals.
NF-B p65 was immunoprecipitated from total cell lysates with anti-p65
antibody and analyzed by SDS–PAGE and autoradiography. P-p65 in-
dicates a phosphorylated form of NF-B p65. (B) PTX-B inhibits TNF-
-induced phosphorylation of the p105 precursor of NF-B p50, but not
of the p50 subunit itself. Analysis was performed as in (A), except that
only a 40-min TNF- stimulation was analyzed and anti-p50 antibody
was used for immunoprecipitation. Note that this antibody precipitates
both p50 and p105. P-p105 and P-p50 indicate phosphorylated forms of
the proteins.
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phosphorylation of the NF-B family of proteins. The
phosphorylation of these proteins is carried out by ki-
nases belonging to the IKK complex, which also phos-
phorylates IB (Cohen et al., 2001; Heissmeyer et al.,
1999; Koul et al., 2001; Orian et al., 2000; Sakurai et al.,
1999; Sizemore et al., 1999, 2002; Wang and Baldwin,
1998). In particular, both IB and p105 (NF-B p50
precursor) are phosphorylated predominantly by IKK
(Orian et al., 2000). However, while PTX-B stimulated
IB phosphorylation, it inhibited phosphorylation of the
p105 and NF-B p65 subunit. Therefore, it appears that
IKK is not the target of PTX-B.
Recent studies demonstrated that phosphorylation of
the p65 subunit of NF-B plays an essential role in
up-regulation of the transcriptional activity of NF-B, in-
dependent of its binding activity (Li et al., 1999; Mercurio
et al., 1999; Sakurai et al., 1999; Schwabe et al., 2001;
Vanden Berghe et al., 1998; Wang and Baldwin, 1998).
While the effect of phosphorylation on NF-B nuclear
transport has not been formally demonstrated, phosphor-
ylation is a common mechanism for nuclear import and
export regulation (Jans, 1995; Jans and Hubner, 1996).
The p65 molecule has several potential phosphorylation
sites for different kinases. The IKK complex induces
phosphorylation of Ser-536 (Sakurai et al., 1999), protein
kinase A phosphorylates Ser-276 (Zhong et al., 1998),
and Ser-529 is phosphorylated by an undefined protein
kinase in response to TNF- (Wang and Baldwin, 1998).
The IKK is required for p65 phosphorylation at the basal
level of NF-B activity, whereas IKK phosphorylates p65
solely in response to cytokine induction (Sizemore et al.,
2002). Our results demonstrate PTX-B-induced suppres-
sion of NF-B p65 activity in both TNF--activated and
non-activated cells. Together with demonstrated activa-
tion of the IB phosphorylation and the lack of a PTX-B
suppressive effect on NF-B p50 phosphorylation, these
results suggest that the effect of PTX-B is not mediated
by suppression of IKK activity.
What could then be a mechanism of NF-B-directed
PTX-B activity? The delayed character of the PTX-B sup-
pressing effect on NF-B p65 and p105 phosphorylation
suggests that PTX-B signaling might initiate synthesis
and cytoplasmic accumulation of a phosphorylation in-
hibitor, such as phosphatase. Inhibition of p65 phosphor-
ylation might down-regulate its nuclear import, stimulate
nuclear export, or stimulate degradation of the protein,
thus reducing its steady-state nuclear concentration and
transcriptional activity of p65/p65 homo- and p65/p50
heterodimers.
In conclusion, our results indicate that PTX-B specifi-
cally inactivates the p65, but not the p50, subunit of
NF-B. This effect appears to be mediated through a
decrease of p65 nuclear steady-state level and corre-
lates with suppression of p65 phosphorylation. In con-
trast, phosphorylation and nuclear accumulation of p50
is not affected by PTX-B. Since the p65 subunit of NF-B
is a strong transcriptional activator of HIV-1 LTR pro-
moter activity, whereas p50 does not activate HIV-1 tran-
scription (Pazin et al., 1996), our results help explain the
observed inhibitory activity of PTX-B on HIV-1 replication
(Alfano et al., 2001). It should be noted that we analyzed
the effect of PTX-B on HIV-1 LTR-driven transcription of
an extrachromosomal construct. This may explain the
incomplete inhibition compared to results reported by
Alfano et al. (2001). Indeed, p65 was shown to provide a
much more potent stimulation of HIV-1 promoter activity
in the context of a chromatin-organized template than in
the context of a naked DNA template (Pazin et al., 1996;
West et al., 2001).
Future studies will further investigate the molecular
mechanisms underlying the observed inhibitory activity
of PTX-B on NF-B p65 phosphorylation and nuclear
level. Understanding these mechanisms will help design
a novel type of anti-HIV agent that targets intracellular
signaling mechanisms in order to inhibit reactivation of
the latent HIV-1 provirus. Such agents should further
improve the efficiency of HAART and should help keep
infection at bay when HAART has to be withdrawn.
EXPERIMENTAL PROCEDURES
Reagents
Pertussis toxin B-oligomer (Calbiochem, San Diego,
CA) was dissolved in sterile PBS to a final concentration
of 50 g/ml and stored at 4°C. TNF, rabbit anti-IB,
and anti-phospho IB antibodies were also from Cal-
biochem. Mouse anti-histone H1 (AE-4) and anti-p65
NF-B (F-6)X monoclonal, and rabbit anti-p65 NF-B
(C-20), anti-p50 NF-B (H-119), and (H-119)X polyclonal
antibodies were purchased from Santa Cruz Biotechnol-
ogy, Inc. (Santa Cruz, CA). Mouse anti-actin (AC-40)
monoclonal antibodies were from Sigma (St. Louis, MO).
Luciferase and dual-luciferase assay systems were from
Promega (Madison, WI). RPMI 1640 phosphate-free me-
dium was from Specialty Media (Phillipsburg, NJ).
Cell cultures
U-937 human monoblastic leukemia cells were pur-
chased from ATCC (Rockville, MD) and maintained at
37°C in 5% CO2 in RPMI 1640 supplemented with 10%
(v/v) FCS (HyClone), 100 units/ml penicillin, and 100
units/ml streptomycin.
Plasmid constructs
A 789-bp fragment containing the HIV-1LAI 5 LTR (nt
1–789; numbering is according to the LAI provirus where
nt  1 is the start of U3 in the 5 LTR) was prepared from
pLTR-CAT (Van Lint et al., 1994) by digestion with PstI,
blunt-ending of the 3 overhang with T4 DNA polymer-
ase, and digestion with XbaI successively, and this frag-
ment was then cloned in pGL2-Basic (Promega) digested
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with Acc65I, blunted with Klenow polymerase, and di-
gested with NheI. The resulting plasmid was designated
pLTRluc-wt. To construct pLTRluc-mut-B, pLTRluc-wt
was used as a substrate for mutagenesis of the two B
sites by the Quick Change Site-Directed Mutagenesis
method (Stratagene). Mutations were generated with the
following pair of mutagenic oligonucleotide primers
(mutations are highlighted in bold and B sites are
underlined on the coding strand primer): CV211/CV212:
5-CGAGCTTGCTACAACTCACTTTCCGCTGCTCACTTT-
CCAGGGAGG-3. To construct pLTRluc-mut-Sp1(I,II,III),
pLTRluc-wt was used as a substrate for mutagenesis of
the three Sp1 sites by the Quick Change Site-Directed
Mutagenesis method (Stratagene). Mutations were gen-
erated with the following pair of mutagenic oligonucleo-
tide primers (mutations are highlighted in bold and Sp1
sites are underlined on the coding strand primer): CV421/
CV422: 5-GGGGACTTTCCAGGGATTCGTGGCCTGTTC-
GGGACTGGTTAGTGGCGAGCCCTC-3. To construct
pLTRluc-TAR, pLTRluc-wt was used as a substrate for
the mutagenesis of the TAR region by the Transformer
Site-Directed Mutagenesis method (Clontech, Palo Alto,
CA). The 3-nt bulge of TAR (nt 476–478) was deleted with
the following mutagenic oligonucleotide (CV61):
5-Gnt494AGAGCTCCCAGGCTCTCTGGTCTAACC-3. The
oligonucleotide (CV68) 5-CGGTCGACGGTACCAGACAT-
GATAAG-3, changing a unique BamHI restriction site in
pLTRluc-wt into a KpnI site (highlighted in bold), was
used for selection during mutagenesis. All mutated con-
structs were fully resequenced after identification by
cycle sequencing using the Thermosequenase DNA se-
quencing kit (Amersham). The reporter construct pL-
TRluc-mut-AP-1(I,II,III)/NF-AT was previously described
(Van Lint et al., 1997).
Plasmids pRSV-p50 and pRSV-p65 were obtained from
Dr. Gary Nabel and Dr. Neil Perkins through the AIDS
Research and Reference Reagent Program (Division of
AIDS, NIAID, NIH).
Transient transfection and luciferase assays
Transfections of U-937 cells with recombinant plas-
mids were performed using FuGene 6 Transfection Re-
agent (Roche, Indianapolis, IN). Suspensions of 2  106
exponentially growing cells were transfected with 1 g of
recombinant plasmid DNA encoding firefly luciferase
controlled by HIV-1 LTR sequences either alone or to-
gether with 0.1 g of HIV-1 Tat-encoding plasmid
pcDNA1/Tat, kindly provided by Dr. Chiara Bovolenta.
Also, as a control, we used Renilla luciferase-encoding
plasmid pRL-CMV (Promega). For experiments with the
expression vectors for p65 and p50, 2  106 U-937 cells
were cotransfected with a pLTRluc-wt construct (1 g)
and pRSV-p65 or pRSV-p50 individually (0.01 g each) or
together (0.005 g each). Transfected cells were cultured
in the presence or absence of PTX-B (2.5 nM) for 24, 48,
or 72 h. Cells were harvested and washed twice with
PBS. Luciferase activity was measured using the Lucif-
erase (for firefly luciferase-encoding plasmids) and Dual-
Luciferase (for pRL-CMV plasmid) assay systems (Pro-
mega) as suggested by the manufacturer.
Cell fractionation and extraction of nuclear proteins
Cytoplasmic and nuclear fractions were prepared from
U-937 cells preincubated with or without PTX-B (2.5 nM)
and TNF- (0.1 ng/ml). Cells were washed twice with
cold phosphate-buffered saline and lysed in low-salt
buffer A (20 mM HEPES, pH 7.9, 5 mM KCl, 0.5 mM
MgCl2, 0.5 mM DTT, and Roche protease inhibitor cock-
tail), supplemented with 0.5% Triton X-100. Nuclei were
precipitated at 1000 g and washed with cold buffer A;
cytoplasmic fractions were separated and cleared at
20,000 g for 15 min. Nuclear proteins were extracted from
nuclear precipitates by incubation in high-salt buffer B
(20 mM HEPES, pH 7.9, 500 mM KCl, 0.5 mM MgCl2, 0.5
mM DTT, and Roche protease inhibitor cocktail) for 3 h at
4°C. Protein concentrations were determined by Lowry
method using DC Protein Assay kit (Bio-Rad, Hercules,
CA).
Western blot analysis
The cytoplasmic lysates and nuclear extracts were
separated by SDS–PAGE, transferred to PVDF mem-
branes, and analyzed using above-listed antibodies.
Specific bands were visualized by ECL (Amersham,
Buckinghamshire, England).
Analysis of NF-B phosphorylation in vivo
Cells were preincubated with 2.5 nM PTX-B in com-
plete RPMI 1640 media for 24 h. Following double wash-
ing in PBS, cells were incubated in phosphate-free RPMI
1640 for 24 h and then incubated with 1 mCi/ml of
[32P]orthophosphate (Amersham Pharmacia Biotech, Pis-
cataway, NJ) for 2 h. After stimulation with TNF- (0.1
ng/ml) for various time intervals, cells were harvested,
washed in PBS, and lysed in RIPA buffer (50 mM Tris–
HCl, pH 8.0; 100 mM NaCl; 1 mMMgCl2; 1% Triton X-100).
The NF-B subunits were immunoprecipitated with anti-
p65 and anti-p50 antibodies, separated on 10–20% SDS–
PAG and autoradiographed.
Electrophoretic mobility shift assay (EMSA) and
supershift assay
Assays were performed according to previously pub-
lished protocol (Alfano et al., 2001). In brief, the oligonu-
cleotide corresponding to HIV-1 LTR NF-B binding sites,
5-GCTACAAGGGACTTTCCGCTGGGGACTTTCCAGG-3,
was annealed to its complementary strand and labeled
with [32P]ATP (Amersham Pharmacia Biotech) to 50,000
cpm/ng using polynucleotide kinase (MBI Fermentas,
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Amherst, NY). Equal amounts (10 g) of nuclear extracts
of the PTX-B treated/untreated U-937 cells in buffer B
(see above) were added to 10 l of a binding reaction
buffer (20 mM HEPES, pH 7.9, 25% glycerol, 50 mM KCl,
0.2 mM EDTA, 0.5 mM DTT, and Roche protease inhibitor
cocktail) supplemented with 1 l (5 mg/ml) of poly(dI:dC)
(Roche) and 1 l (10 mg/ml) of BSA (Sigma). For super-
shift analysis, the aliquots of the same nuclear extracts
were incubated with 1 l (2 mg/ml) of anti-p65 NF-B
(F-6)X or anti-p50 NF-B (H-119)X antibodies (Santa Cruz
Biotechnology) for 20 min at room temperature. One
microliter (0.5 ng) of [32P]ATP-labeled double-strand oli-
gonucleotide probe was added to all samples, and mix-
tures were incubated for 45 min at room temperature and
then run on a nondenaturing 5% PAG in 1  TBE. Gels
were dried, and radioactive bands were analyzed by
autoradiography.
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